Want to see EVH full AI Analyst Report?
EVH Stock Chart & Stats
$4.59
$0.00(0.00%)
At close: 4:00 PM EDT
$4.59
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.10 - $8.30
Previous CloseN/A
Volume827.94K
Average Volume (3M)2.22M
Market Cap
$516.68M
Enterprise Value$1.44B
Total Cash (Recent Filing)$115.70M
Total Debt (Recent Filing)$970.43M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 05, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.49
Shares Outstanding113,059,330
10 Day Avg. Volume2,130,941
30 Day Avg. Volume2,215,840
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap2.79
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit5.32
Enterprise Value/Ebitda-4.50
Forecast
1Y Price Target
$5.56Price Target Upside21.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.17
Revenue Forecast (FY)$2.64B
Bulls Say, Bears Say
Bulls Say
Customer Retention And ExpansionRenewals with three major customers improve revenue visibility and demonstrate the value of Evolent’s offerings. Strong engagement at new Highmark and Aetna launches also supports expansion within important payer relationships and can strengthen the recurring contract base.
AI-enabled ProductivityScaling Auth Intelligence can make authorization workflows faster and more efficient while preserving clinical quality. Higher automation and productivity should support customer value, improve operating leverage, and provide a durable technology-enabled advantage as adoption expands.
Recurring Outsourced-services ModelRecurring contracts for delegated clinical and administrative functions can create durable revenue visibility and deepen customer relationships. Combining software with operational services may also make Evolent harder to replace than a standalone point solution.
Bears Say
Deep Losses And Margin PressurePersistent net losses and lower gross margins show that revenue growth has not yet translated into durable profitability. Continued cost-of-services or mix pressure could limit reinvestment capacity and weaken the earnings contribution from future contract growth.
High Net LeverageElevated net debt increases financial pressure while the company is still loss-making and cash generation remains modest. Refinancing needs and upcoming maturities may constrain investment, reduce strategic flexibility, and keep capital structure improvement a central execution requirement.
Membership And Medical-cost HeadwindsExpected membership declines can reduce covered volumes and pressure revenue in affected programs, while elevated medical expense ratios can compress economics. Together, these factors create ongoing execution risk for growth and margin recovery over the next several quarters.
EVH FAQ
What was Evolent Health’s price range in the past 12 months?
Evolent Health lowest stock price was $2.10 and its highest was $8.30 in the past 12 months.
What is Evolent Health’s market cap?
Evolent Health’s market cap is $516.68M.
When is Evolent Health’s upcoming earnings report date?
Evolent Health’s upcoming earnings report date is Nov 05, 2026 which is in 18 days.
How were Evolent Health’s earnings last quarter?
Evolent Health released its earnings results on Aug 06, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.03.
Is Evolent Health overvalued?
According to Wall Street analysts Evolent Health’s price is currently Undervalued.
Does Evolent Health pay dividends?
Evolent Health does not currently pay dividends.
What is Evolent Health’s EPS estimate?
Evolent Health’s EPS estimate is 0.06.
How many shares outstanding does Evolent Health have?
Evolent Health has 113,059,330 shares outstanding.
What happened to Evolent Health’s price movement after its last earnings report?
Evolent Health reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 16.558%.
Which hedge fund is a major shareholder of Evolent Health?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.56 (21.04% Upside)
$5.56 (21.04% Upside)
Blogger Sentiment
Bullish
EVH Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.41%
12-Months-Change
Fundamentals
Return on Equity
-99.16%
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evolent Health
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a balanced mix of strong operational execution and growth momentum (notably 31% QoQ revenue growth, a 50% jump in Performance Suite revenue, raised 2026 revenue guidance, a large oncology deal, and meaningful AI progress) alongside notable near-term challenges (elevated MER, membership headwinds from Medicaid/exchange, timing variability in EBITDA recognition, and elevated net leverage). Management expressed confidence in 2027 growth (>25% revenue) and margin recovery driven by AI, Performance Suite maturation and cost actions, but acknowledged material macro- and client-specific risks that temper near-term financial clarity.View all EVH earnings summariesEVH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$5.56
▲(21.04% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Teladoc
―
Health Catalyst
―
American Well
―
Privia Health Group
―
BrightSpring Health Services, Inc.
―
Ownership Overview
2.76% Insiders
13.34% Mutual Funds
0.51% Other Institutional Investors
70.35% Public Companies and
Individual Investors









